Dallas-Fort Worth, Texas (PRWEB) November 08, 2015
A Study by orthopedic surgeon and stem cell specialist, Dr. Wade McKenna of the Riordan-McKenna Institute entitled, “Outpatient Treatment of Compensated Cuff Arthropathy Using Inlay Arthroplasty With Subscapularis Preservation” is published in the December edition of Techniques in Shoulder and Elbow Surgery.
Dr. McKenna is co-founder and chief medical officer of the Riordan-McKenna Institute of Regenerative Orthopedics (RMI) in Southlake, Texas. Co-author of this work is Troy Chandler, PA-C from North Central Texas Orthopedics in Decatur, Texas.
Rotator cuff tear arthropathy sometimes develops in patients who have had a very large, long-standing rotator cuff injury. In CTA, changes in the shoulder due to the rotator cuff tear cause arthritis and lead to destruction of joint cartilage.
The Shoulder HemiCAP® restoration procedure is designed to match the shape and contour of individual patient’s cartilage and joint surface and be an ideal alternative to shoulder replacement. It simply recreates a smooth surface where the cartilage has worn away — similar to a filling for a tooth cavity.
The study examined a consecutive series of 50 CTA patients treated by Dr. McKenna from 2007 to 2015. It concluded that resurfacing the humeral head (shoulder bone) using a HemiCAP shoulder implant preserves the joint and avoids bone loss and complications associated with more invasive procedures like stemmed arthroplasty or total shoulder replacement.
Furthermore, the HemiCAP procedure disrupts the degenerative cycle of early-stage CTA, effectively addresses causes of pain, and avoids further muscle imbalance. The latter is achieved by a special deltoid muscle-splitting approach that leaves the tendon under the shoulder bone intact.
All of these advantages resulted in accelerated recovery and rehabilitation for patients.
“We are very pleased with the positive outcome of this study. Although we specialize in non-surgical stem cell interventions at RMI, sometimes, as in the case of CTA, surgical intervention is indicated. That’s why it’s important for patients to seek out an experienced orthopedic surgeon who, in addition to orthopedic expertise, is well versed on the latest advances in stem cell therapy. A surgeon needs both to know when stem cell therapy may be effective and when surgery, perhaps augmented with biologics like bone marrow aspirate concentrate (BMAC) and AlphaGEMS amniotic tissue product, is a better option,” commented Dr. McKenna.
About Riordan-McKenna Institute (RMI)
RMI specializes in non-surgical treatment of acute and chronic orthopedic conditions using *AlphaGEMS flowable amniotic tissue allograft and bone marrow aspirate concentrate (BMAC) that is harvested using the patented BioMAC bone marrow aspiration cannula. Common conditions treated include meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis. RMI also uses AlphaPATCH amniotic membranes as part of a complete wound care treatment regimen.
RMI also augments orthopedic surgeries with BMAC and AlphaGEMS to promote better post-surgical outcomes.
BMAC contains a patient’s own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. AlphaGEMS is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.
*AlphaGEMS and AlphaPATCH products are produced by Amniotic Therapies Inc. from donated amniotic tissue after normal healthy births. For more information about AlphaGEMS, please visit: https://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/
801 E. Southlake Blvd.
Tel: (817) 776-8155
Toll Free: (877) 899-7836
Fax: (817) 776-8154
For the original version on PRWeb visit: http://www.prweb.com/releases/2015/11/prweb13068117.htm